OpGen
Microbial Genetic Analysis - OpGenOpGen.
Launch date
Employees
Market cap
€15.8m
Enterprise valuation
€28m (Public information from Sep 2024)
Share price
$2.02 OPGN
Gaithersburg Maryland (HQ)
Financials
Estimates*
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.9m | 3.5m | 4.2m | 4.3m | 2.6m | 3.4m | 2.6m |
| % growth | (8 %) | 19 % | 20 % | 2 % | (39 %) | 31 % | (24 %) |
| EBITDA | (12.4m) | (11.0m) | (21.4m) | (23.1m) | (22.2m) | (14.2m) | (17.0m) |
| % EBITDA margin | (422 %) | (313 %) | (508 %) | (535 %) | (850 %) | (416 %) | (654 %) |
| Profit | (13.4m) | (12.4m) | (26.2m) | (34.8m) | (37.3m) | (32.7m) | (7.5m) |
| % profit margin | (454 %) | (356 %) | (622 %) | (808 %) | (1430 %) | (956 %) | (290 %) |
| EV / revenue | 2.9x | 1.3x | 13.1x | 6.5x | 5.7x | 4.7x | 1.8x |
| EV / EBITDA | -0.7x | -0.4x | -2.6x | -1.2x | -0.7x | -1.1x | -0.3x |
| R&D budget | 5.7m | 5.1m | 10.0m | 10.9m | 8.2m | 4.7m | - |
| R&D % of revenue | 193 % | 146 % | 236 % | 253 % | 313 % | 138 % | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
$5.0m | Series B | ||
| N/A | $4.1m | Debt | |
| N/A | $4.0m | Debt | |
$17.0m | Series B | ||
| N/A | $3.5m | Debt | |
| N/A | $4.0m | Debt | |
| N/A | $1.2m | Debt | |
| N/A | N/A | IPO | |
$10.4m | Post IPO Equity | ||
* | N/A | $7.5m | Post IPO Equity |
* | N/A | $3.5m | Post IPO Equity |
* | $3.0m | Post IPO Equity | |
| Total Funding | €20.0m | ||
